Recent Finacing
Recent Raise
Neurophth develops AAV gene therapies for ocular diseases, advancing NR082 for ND4-LHON plus ND1-LHON, optic atrophy, glaucoma and vascular retinopathies, with GMP manufacturing in Suzhou and US subsidiaries.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Neurophth Therapeutics.
